Status:

WITHDRAWN

IC14 in Adult Patients With Dengue Fever

Lead Sponsor:

Implicit Bioscience

Conditions:

Dengue Fever

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever \> 38°C for \< 48 hour...

Detailed Description

The study will be conducted in two parts and will include an open label phase of a single dose of IC14 (Part A) and a randomized phase of multiple doses of IC14 and placebo (Part B). Up to 52 patients...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Fever \> 38°C for \< 48 hours and clinical presentation consistent with dengue fever.
  • Positive NS1 strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR) assay for dengue virus.
  • Informed consent form signed and dated by the patient.
  • Subject able to give informed consent and able to comply with all study visits and all study procedures.
  • Females of childbearing potential should be using and committed to continue using acceptable birth control methods.
  • Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
  • Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
  • Stable hormonal contraception for at least 3 months prior to study through study completion; or
  • Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
  • To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.
  • Exclusion Criteria
  • One or more of the following dengue warning signs and symptoms:
  • Intense and continuous abdominal pain (referred pain or on palpation);
  • Persistent vomiting;
  • Fluid accumulation (ascites, pleural effusion, or pericardial effusion);
  • Postural hypotension and/or collapse;
  • Painful hepatomegaly \> two centimeters below the right costal margin;
  • Mucosal bleeding;
  • Major bleeding (hematemesis and/or melena);
  • Lethargy and/or irritability;
  • Diminished urine output;
  • Hypothermia;
  • Progressive increase in hematocrit or 20% above baseline or normal for age;
  • Abrupt drop in platelets;
  • Respiratory discomfort.
  • One or more of the following signs and symptoms of severe dengue, such as:
  • Severe plasma extravasation, leading to shock evidenced by one or more of the following:
  • Tachycardia;
  • Cold distal extremities;
  • Weak, thready pulse;
  • Slow capillary refill (\> 2 seconds);
  • Pulse pressure \< 20 mmHg;
  • Tachypnea; or
  • Oliguria (\<1.5 mL/kg/hr).
  • Systolic blood pressure \< 90 mmHg or decrease \>40 mmHg;
  • Cyanosis;
  • Fluid accumulation with respiratory discomfort;
  • Severe bleeding; or
  • Severe organ impairment, evidenced by one or more of the following:
  • Liver impairment (AST \>1000 U/L, international normalized ratio \>1.5);
  • Renal impairment (serum creatinine ≥1.5 mg/dL); or
  • Myocarditis, pericarditis, or clinical heart failure (by chest x-ray, echocardiography, electrocardiogram, or cardiac enzymes if available).
  • Female who is pregnant, lactating or of childbearing potential.
  • Self-reported or suspected congenital or acquired immunodeficiency (including HIV infection); or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the previous 3 months).
  • Prior vaccination against dengue fever.
  • Significant chronic illness that, in the opinion of the Investigator, would interfere with study validity, conduct or completion.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2020

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT03875560

    Start Date

    May 1 2019

    End Date

    June 1 2020

    Last Update

    March 14 2019

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    IC14 in Adult Patients With Dengue Fever | DecenTrialz